Tezspire Drives 69% Remission in Esophageal Disease Trial, With Benefit Held to 52 Weeks
AMGN sits 49% above its 52-week low of $288.
Summary
Tezspire, co-developed by Amgen and AstraZeneca, produced disease remission in 69% of patients on the 420 mg dose and 65% on the 210 mg dose at 24 weeks, versus 3.5% on placebo, in eosinophilic esophagitis. The effect held through 52 weeks — 67.8% and 63.3% remission versus 5.4% for placebo — and swallowing-difficulty scores improved by 18.8 and 22 points against a 14.7-point placebo reduction. This extends the August topline readout with the actual remission rates and durability, which is what matters for a label expansion beyond Tezspire's existing severe-asthma approvals. The drug would compete directly with Sanofi and Regeneron's Dupixent, making this a share-shift story for Regeneron as much as an upside for Amgen. Amgen shares are near a 52-week high, and this adds a second pipeline positive after the August Tezspire asthma win, though the Tavneos withdrawal proposal and the $10.7B IRS dispute remain unresolved overhangs.
At the time of this announcement, AMGN was trading at $429.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $229.7B. The 52-week trading range was $288.00 to $447.03. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.